- Clinical-stage biotech Geron Corporation ( NASDAQ: GERN ) announced several recent additions to the company’s senior commercial leadership on Wednesday ahead of the planned launch of its blood cancer therapy imetelstat.
- Early this month, Geron ( GERN ) said that imetelstatin, its only product candidate reached the primary endpoint in a Phase 3 trial for patients with low-risk myelodysplastic syndromes (MDS).
- The company expects to submit marketing applications for the candidate in the U.S. and Europe in mid-2023 and H2 2023, expecting market launches in H1 2024 and by the end of next year, respectively.
- Recent additions to the Gern’s ( GERN ) commercial leadership include Lorraine Shui, former U.S. brand lead for sickle cell marketing at Novartis ( NVS ) ( OTCPK:NVSEF ), who serves as the Vice President, Marketing.
- Former Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) executive Peter Avalos has joined the company as Vice President, Trade and Channel Relations.
- Read: Seeking Alpha contributor Terry Chrisomalis cites Geron ( GERN ) as a “great speculative biotech play.”
For further details see:
Geron lines up commercial leadership for imetelstat launch